Product Overview
【Drug Name】
Jin Ao Kang (Omeprazole Enteric-coated Capsules)
【Indications】
For gastric ulcer, duodenal ulcer, stress ulcer, reflux esophagitis and Zollinger-Ellison syndrome (gastrinoma).
【Usage and Dosage】
Omeprazole enteric-coated capsules are taken orally, do not chew. (1) Peptic ulcer: 20 mg (1 capsule) once, 1-2 times a day. Swallow in the morning or once in the morning and evening. The treatment course for gastric ulcer is usually 4-8 weeks. (2) Reflux esophagitis: 20-60 mg (1-3 capsules) once. 1-2 times a day. Swallow in the morning or once in the morning and evening. The treatment course is usually 4-8 weeks. (3) Zollinger-Ellison syndrome: 60 mg (3 tablets) once a day. The total daily dose can be adjusted to 20-120 mg (1-6 tablets) according to the condition. If the total daily dose exceeds 80 mg (4 tablets), it should be divided into two doses.
[Ingredients] Omeprazole.
[Properties] The contents of this product are white or off-white enteric-coated pellets or granules.
[Adverse Reactions] This product is well tolerated. Common adverse reactions include diarrhea, headache, nausea, abdominal pain, gastrointestinal flatulence and constipation. Occasionally, increased serum aminotransferase (ALT, AST), rash, dizziness, drowsiness, insomnia, etc. are observed. These adverse reactions are usually mild and can disappear automatically. They are not related to the dose. No serious adverse reactions have been observed in long-term treatment, but gastric mucosal cell hyperplasia and atrophic gastritis may occur in some cases.
[Contraindications] This product is contraindicated for patients who are allergic to this product, those with severe renal insufficiency and infants. [Precautions]
1. When treating gastric ulcers, the possibility of ulcer-type gastric cancer should be ruled out first, as this product may alleviate symptoms and thus delay treatment.
2. Use with caution in patients with hepatic and renal insufficiency.
3. This product comes in enteric-coated capsules. Be careful not to chew them when taking to prevent premature release of the drug in the stomach and affecting efficacy.
[Drug Interactions]
This product may delay the elimination of drugs metabolized by the liver, such as diazepam, phenytoin, warfarin, and nifedipine. When using this product with these drugs, the dosage of the latter should be reduced.
[Pharmacological Actions]
Proton pump inhibitor. This drug is a fat-soluble, weakly alkaline drug that is easily concentrated in acidic environments. Therefore, after oral administration, it is specifically distributed in the secretory tubules of the gastric parietal cells. In this highly acidic environment, it is converted into its active form, the sulfenamide. This form then irreversibly binds to the sulfhydryl group of the H+-K+-ATPase (also known as the proton pump) in the secretory membrane of the parietal cells via a disulfide bond, forming a sulfenamide-proton pump complex. This inhibits the enzyme's activity and blocks the final step in gastric acid secretion. Therefore, this drug has a strong and long-lasting inhibitory effect on gastric acid secretion caused by various causes.
[Storage]
Store in a dry, airtight container protected from light.
[Approval Number]
National Medicine Standard H19991118
[Manufacturer]
Zhejiang Jinhua Kangenbei Biopharmaceutical Co., Ltd.
